博雅生物(300294) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥105,260,618.31, representing a year-on-year increase of 10.33%[8] - Operating revenue for the period was ¥726,575,759.10, reflecting a growth of 22.25% compared to the same period last year[8] - Basic earnings per share were ¥0.24, up 9.09% year-on-year[8] - The total profit for the current period is CNY 134,821,229.85, compared to CNY 116,966,086.05 in the previous period, marking an increase of approximately 15.2%[1] - The net profit attributable to the parent company's owners is CNY 105,260,618.31, compared to CNY 95,401,739.03 in the previous period, reflecting an increase of about 10.5%[72] - The total profit for the current period was ¥398,153,772.92, compared to ¥355,064,194.33 in the previous period, representing an increase of 12.1%[80] - The net profit for the current period was ¥331,076,710.56, compared to ¥298,306,093.07, indicating a growth of 11%[80] Cash Flow - The net cash flow from operating activities was -¥254,529,502.25, indicating a significant decline of 485.18% compared to the previous year[8] - Operating cash inflow for the current period was CNY 1,982,572,766.91, an increase of 25.4% compared to CNY 1,581,832,133.09 in the previous period[91] - Total cash outflow from operating activities was CNY 2,237,102,269.16, up from CNY 1,515,751,477.27, resulting in a net cash flow from operating activities of -CNY 254,529,502.25[94] - The net increase in cash and cash equivalents for the period was -CNY 604,997,342.95, compared to an increase of CNY 224,533,985.17 in the previous period[97] - The ending balance of cash and cash equivalents was CNY 561,450,917.38, down from CNY 722,088,733.48 at the end of the previous period[97] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,176,590,108.56, an increase of 2.04% compared to the end of the previous year[8] - The company's total assets as of September 30, 2019, were ¥4,692,525,635.98, compared to ¥4,582,712,823.61 at the end of the previous year, reflecting a growth of 2.4%[60] - The total liabilities increased to ¥966,275,932.09 from ¥925,462,046.60, marking a rise of 4.0%[63] - The company's total liabilities were approximately CNY 1.30 billion, slightly down from CNY 1.30 billion at the end of 2018[53] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,298[13] - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., held 30.95% of the shares[13] - The controlling shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., committed to not transferring or entrusting the management of shares for 60 months from the date of the company's stock listing[26] - Shareholders including Jiangxi Xinxing Biotechnology Development Co., Ltd. and Shenzhen Ronghua Investment Co., Ltd. committed to not transferring or entrusting the management of shares for 36 months from the date of the company's stock listing[28] Research and Development - Research and development expenses rose by 69.38% to RMB 45,658,776.28, reflecting increased investment in R&D[21] - Research and development expenses for the current period amount to CNY 8,089,428.30, up from CNY 5,280,998.63 in the previous period, which is an increase of about 53.5%[73] - Research and development expenses increased to ¥26,782,246.26, compared to ¥13,978,437.23, marking an increase of 91.6%[87] Financial Commitments and Compliance - The company has committed to resolving potential competition issues with Boya Biological (Guangdong) within three years from April 1, 2017[28] - The company has made commitments to avoid any illegal occupation of funds and assets from Boya Biological and its subsidiaries[33] - The company has committed to not engaging in any business that competes with Boya Biological during the period of being a shareholder[34] - The company will ensure compliance with market principles in any unavoidable related transactions[33] Other Financial Metrics - The company's financial expenses increased by 129.04% to RMB 11,598,714.21, primarily due to higher interest expenses[21] - The company reported a significant increase in cash received from other operating activities, totaling CNY 54,880,585.23, although this was lower than CNY 70,830,666.70 in the previous period[91] - The company reported a credit impairment loss of ¥9,488,734.20, which was not present in the previous period[80]